C-Reactive Protein Increases BBB Permeability: Implications for Obesity and Neuroinflammation

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation.

BACKGROUND/AIMS Acute phase C-reactive protein (CRP), elevated in obesity and inflammation, is a major binding protein for leptin. It is thought that CRP contributes to leptin resistance by preventing leptin from crossing the blood-brain barrier (BBB). Here we determined how CRP interacts with the BBB and whether it deters leptin from reaching CNS targets. METHODS BBB permeability, compartmen...

متن کامل

Investigating relationship between C- reactive protein and obesity in adults

Introduction: Association between plasma high-sensitivity C-reactive protein (CRP) concentrations and cardiovascular disease has been Investigated. C-reactive protein (CRP) is an acute phase reactant which is a marker of inflammation in the body. CRP is made by the liver in response to inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNFα). Adipose ti...

متن کامل

P99: The Role of C- Reactive Protein in Obesity and Neuropathic Diseases

Acute phase C-reactive protein (CRP), raised in obesity and inflammation, is a main binding protein for leptin. It is assumed that CRP contributes to leptin confrontation by preventing leptin from crossing the blood-brain barrier (BBB). Here we defined how CRP cooperates with the BBB and whether it deters leptin from attainment CNS targets. CRP was constant in blood, but did not permeate the BB...

متن کامل

High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study.

The recent results of Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial4 demonstrated that the treatment with rosuvastatin, 20 mg daily, as compared with placebo, was associated with a 44% reduction in the cumulative incidence of major CVD events among 17 802 middle-aged healthy men and women with low levels of low-density lipoprot...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Cellular Physiology and Biochemistry

سال: 2012

ISSN: 1421-9778,1015-8987

DOI: 10.1159/000343302